Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

  1. Cottu, P.
  2. Ring, A.
  3. Abdel-Razeq, H.
  4. Marchetti, P.
  5. Cardoso, F.
  6. Salvador Bofill, J.
  7. Martín, M.
  8. Menon-Singh, L.
  9. Wu, J.
  10. De Laurentiis, M.
Zeitschrift:
Breast

ISSN: 1532-3080,  0960-9776

Datum der Publikation: 2022

Ausgabe: 62

Seiten: 75-83

Art: Artikel

DOI: 10.1016/J.BREAST.2022.01.016 GOOGLE SCHOLAR lock_openOpen Access editor

Objetivos de desarrollo sostenible

Datenquelle: Scopus